Dr. Jonathan Brett Overdevest, MD, PhD

Dr. Overdevest practices at Trustees of Columbia University in the City of New York in Fort Lee, New Jersey.

Dr. Overdevest's NPI, 1881945657, was assigned on September 19, 2012. Dr. Overdevest graduated from UVA School of Medicine in 2012. Dr. Overdevest holds New York license 295290.

Dr. Overdevest's primary practice is Trustees of Columbia University in the City of New York, at 400 Kelby St, Fort Lee, NJ 07024 in Bergen County. The practice phone is (646) 317-7111.

Dr. Overdevest's primary practice is Trustees of Columbia University in the City of New York in Fort Lee, New Jersey. Dr. Overdevest is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Overdevest to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Overdevest practices, 2 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Overdevest's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Overdevest is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Overdevest's licenses on file in 3 states: New York, New Jersey and California.

Dmand AI lists acute sinusitis, chronic nasal allergies, chronic sinusitis and endoscopic sinus surgery among the conditions Dr. Overdevest treats.

CMS data shows 480 Medicare services from Dr. Overdevest across 6 procedure codes in 2024, for 214 Medicare patients. Medicare paid $69,743 for them. Every service was in an office.

CMS counts 214 Medicare patients who saw Dr. Overdevest in 2024. The largest group is 65 to 74, with 91 patients. 68% of them have high cholesterol, and 65% have high blood pressure. 21% are also on Medicaid. Their average risk score is 1.35, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Overdevest's median patient age at 51, with 53% women.

In 2024, Dr. Overdevest wrote 1,048 Medicare Part D claims for 230 patients. 96% of them were for generic drugs. CMS names the drug for 970 of them, across 11 drugs with 11 or more claims each, at $41,215 in total drug cost. In 2023, CMS named 877 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Overdevest for performance year 2024, reported through an alternative payment model (APM). Dr. Overdevest accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 97 papers to Dr. Overdevest, published from 2009 to 2025. 2021 was the busiest year, with 18. The most frequent topics are COVID-19, Olfaction Disorders and Endoscopy. Dr. Overdevest has published most often in Int Forum Allergy Rhinol. Dr. Overdevest's most frequent co-authors are David Gudis, MD, Carol Hanlu Yan, MD and Zara Marzban Patel, MD.

CMS Open Payments shows 39 general payments to Dr. Overdevest from 9 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 76% of the total. Sanofi and Genzyme US Companies paid the most, $11,295.

Dr. Overdevest graduated from UVA School of Medicine in 2012.

Dr. Overdevest is in network with 16 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.